Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men

Clinical Trial ID NCT00458393

PubWeight™ 64.46‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00458393

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010 50.17
2 HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. Lancet Infect Dis 2014 3.65
3 Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav 2013 2.03
4 Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Clin Infect Dis 2015 1.76
5 HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial. J Infect Dis 2014 1.28
6 Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men. PLoS One 2014 1.09
7 Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. J Acquir Immune Defic Syndr 2014 1.00
8 Controlling the HIV/AIDS epidemic: current status and global challenges. Front Immunol 2012 0.92
9 Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial. Proc Natl Acad Sci U S A 2015 0.82
10 Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. Lancet HIV 2016 0.78
11 Role of the pharmacist in pre-exposure chemoprophylaxis (PrEP) therapy for HIV prevention. Pharm Pract (Granada) 2009 0.78
12 Recommendations for the follow-up of study participants with breakthrough HIV infections during HIV/AIDS biomedical prevention studies. AIDS 2013 0.78
13 HIV pre-exposure prophylaxis (PrEP)--a quantitative ethics appraisal. PLoS One 2011 0.78
14 Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing. Antimicrob Agents Chemother 2016 0.77
15 Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. Clin Infect Dis 2016 0.76
16 Persistent HIV Type 1 Seronegative Status Is Associated With Lower CD8+ T-Cell Activation. J Infect Dis 2015 0.75
Next 100